Promising Dual Anticancer and Antimetastatic action by a novel Cu(II) Complex derived from acylhydrazone on human osteosarcoma Models.

LUCÍA SANTA MARIA DE LA PARRA; ADOLFO I. B. ROMO; JOAQUIN RODRIGUEZ-LOPEZ; GUSTAVO A. ECHEVERRÍA; OSCAR E. PIRO; IGNACIO E. LEÓN

Mar del Plata

Congreso; LXVIII REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC); 2024

Osteosarcoma (OS) is a frequent bone cancer, affecting largely children and young adults. Cisplatin (CDDP) has been efficacious in the treatment of different cancer such as OS but the development of chemoresistance and important side effects leading to therapeutic failure. Novel therapies including copper compounds have shown to be potentially effective as anticancer drugs and one alternative to usually employed platinum compounds.The aim of this work is to evaluate the antitumoral activity of a novel copper(II) compound with a acylhidrazone in 2D (monolayer) and 3D (multicellular spheroids) OS models. Using MTT assay we demonstrated that the complex significantly reduced the cell viability in MG-63 IC50: 1,09±0,06µM and in non-tumoral mouse fibroblast L929 IC50: 2,52±0,02µM (p